Author:
Kundranda Madappa N.,Tibes Raoul,Mesa Ruben A.
Publisher
Springer Berlin Heidelberg
Reference94 articles.
1. Aaronson DS, Horvath CM (2002) A road map for those who don’t know JAK-STAT. Science 296:1653–1655
2. Abdel-Wahab O, Pardanani A, Patel J et al (2011) Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 25(7):1200–1202
3. Barosi G, Ambrosetti A, Centra A et al (1998) Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia. Blood 91:3630–3636
4. Barosi G, Viarengo G, Pecci A et al (2001) Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. Blood 98:3249–3255
5. Baxter EJ, Scott LM, Campbell PJ et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365:1054–1061